SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,945,809 shares, an increase of 24.7% from the January 15th total of 1,559,953 shares. Currently, 5.5% of the company’s shares are short sold. Based on an average daily trading volume, of 488,835 shares, the short-interest ratio is currently 4.0 days. Based on an average daily trading volume, of 488,835 shares, the short-interest ratio is currently 4.0 days. Currently, 5.5% of the company’s shares are short sold.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently modified their holdings of SABS. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at about $34,000. State Street Corp purchased a new stake in SAB Biotherapeutics in the fourth quarter valued at approximately $49,000. ADAR1 Capital Management LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $30,000. Fifth Lane Capital LP acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $56,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics during the third quarter worth approximately $32,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on SABS. Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, December 18th. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. Guggenheim began coverage on SAB Biotherapeutics in a research note on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. UBS Group initiated coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Stock Up 0.8%

SABS stock traded up $0.03 during mid-day trading on Tuesday, reaching $3.88. The company had a trading volume of 480,860 shares, compared to its average volume of 373,239. The firm has a fifty day simple moving average of $3.97 and a 200 day simple moving average of $3.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The company has a market capitalization of $184.73 million, a price-to-earnings ratio of -1.26 and a beta of 0.59. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. Analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.